|
EP3699299A1
|
|
Process for classification of glioma
|
|
EP3564670A1
|
|
Antibodies against trim9 and/or trim67 in paraneoplastic neurological syndromes
|
|
FR3067720A1
|
|
Molecular label for the traceability of samples subject to subsequent analysis
|
|
EP3377882A1
|
|
Method for diagnosing anomalies in the coagulation of blood
|
|
WO2017064406A1
|
|
Prosthesis for creating a vascular anastomosis
|
|
EP3251591A1
|
|
System for determining a coronary pulse wave velocity
|
|
FR3050535A1
|
|
ANTIBODY ANTI IL17
|
|
EP3060110A1
|
|
Electrophysiological method for assessing the effectiveness of a hearing aid
|
|
EP3054962A1
|
|
Puma protein expression vector and use thereof in gene therapy
|
|
FR3021976A1
|
|
Biological marker for evaluating the pro-inflammatory level depending on the functional contribution of il-17 in an individual
|
|
FR2992158A1
|
|
Device for evaluating the cognitive capacity of a patient
|
|
FR2988479A1
|
|
Method for determining the susceptibility to nosocomial infections
|
|
FR2977696A1
|
|
METHOD FOR ESTIMATING MOTION IN A DYNAMIC IMAGE SEQUENCE
|
|
FR2970418A1
|
|
DEVICE FOR OPTIMIZING THE GLYCEMIA OF A PATIENT
|
|
FR2963832A1
|
|
Method for quantifying the potentiating effect of fibrinogen on the generation of thrombin and its applications
|
|
FR2960882A1
|
|
Co-culture of mononucleated cells and mesenchymal cells for the production of il-17 production cells
|
|
FR2957520A1
|
|
Device and method for solving or suspension of pharmaceutical or food products
|
|
FR2948769A1
|
|
Method for diagnosing toxoplasmosis
|
|
FR2943687A1
|
|
METHOD FOR IN VITRO SCREENING OF CARDIOPATHIES.
|
|
FR2934492A1
|
|
Association of a ligand of tlr3 and an agent acting on the intrinsic pathway of "apoptosis" in the treatment of cancer.
|
